BlackDoctor6d
Have Diabetic Macular Edema? This Clinical Trial Could Be For You
The ELEVATUM study is designed to investigate how faricimab impacts DME in Black Americans. By enrolling, you'll contribute ...
PharmiWeb3d
Global Diabetic Macular Edema Market Projected to Reach USD 4,642.9 Million by 2034, Driven by Rising Incidence of Diabetes | FMI
The global diabetic macular edema market is on a steady growth trajectory, with an expected valuation of approximately USD 4,120.9 million in 2024. The market is poised to surpass USD 4,642.9 million ...
FiercePharma13d
After prior trial flop, EyePoint's Duravyu bounces back with promising data in DME
Earlier this year, EyePoint Pharmaceuticals’ drug-device combo Duravyu missed the mark in a non-proliferative diabetic ...
FierceBiotech3d
Struggling AlloVir finds new identity by merging into eye disease biotech
AlloVir has been reeling ever since a trio of phase 3 trial failures last year led the company to shed almost all of its staff. | AlloVir has been reeling after a trio of phase 3 trial failures last ...
EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss
EyePoint Pharmaceuticals' shares rise as interim Phase 2 VERONA trial data shows Duravyu improves visual acuity and anatomy ...
The Pharma Letter3d
Santen and Arctic Vision eye opportunity in China
Japanese ophthalmology company Santen Pharmaceutical has crossed the East China Sea in its latest collaboration, announced on ...
Rezolute’s Promising Growth: Buy Rating Backed by Financial and Clinical Advancements
Maxim Group analyst Jason McCarthy has maintained their bullish stance on RZLT stock, giving a Buy rating yesterday. Jason McCarthy has given ...